Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022

SELL
$1.33 - $2.28 $59,989 - $102,839
-45,105 Closed
0 $0
Q1 2022

Apr 21, 2022

BUY
$1.73 - $4.06 $51,401 - $120,630
29,712 Added 193.02%
45,105 $93,000
Q4 2021

Feb 03, 2022

BUY
$3.5 - $5.68 $53,875 - $87,432
15,393 New
15,393 $58,000

Others Institutions Holding ADAP

About Adaptimmune Therapeutics PLC


  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $121M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Inspire Advisors, LLC Portfolio

Follow Inspire Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Inspire Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Inspire Advisors, LLC with notifications on news.